<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884295</url>
  </required_header>
  <id_info>
    <org_study_id>EXEVIR0101</org_study_id>
    <secondary_id>2020-005299-36</secondary_id>
    <nct_id>NCT04884295</nct_id>
  </id_info>
  <brief_title>Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19</brief_title>
  <official_title>A 2-part Clinical Study Including a First in Human, Open Label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double Blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy and Safety of XVR011 in Patients Hospitalised for Mild to Moderate Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ExeVir Bio BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ExeVir Bio BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 part study where the first part (Phase 1) evaluates the safety of XVR011 and aims&#xD;
      to identify the recommended Phase 2 dose. The second part (Phase 2) follows after the part 1&#xD;
      and evaluates whether XVR011 added to standard of care in patients hospitalised for mild to&#xD;
      moderate COVID-19 is a safe, well tolerated, and effective treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1 is open-label, single ascending dose; Phase 2 is double-blind, randomised, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects, Investigator and/or employees of the investigational site and sponsor personnel will remain blinded to each subject's assigned study treatment throughout the course of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Adverse Events (all and serious)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recovery (i.e., clinical status reaching level 1 to 3 of the 8-point ordinal scale)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of oxygen supplementation</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects requiring mechanical ventilation and/or ICU transfer</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with COVID-19 related symptoms</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the viral load (RT-qPCR) of nasopharyngeal samples</measure>
    <time_frame>Up to Day 8/ Day of Discharge</time_frame>
    <description>Phase 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Adverse Events (all and serious)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Adverse Events of Special Interest</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the serum concentration-time curve (AUC)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum terminal elimination half-life (t1/2)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of anti-drug antibody (ADA) to XVR011</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1/2</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>XVR011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: low - medium - high dose; Phase 2: recommended dose from Phase 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2 only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XVR011</intervention_name>
    <description>Single dose of XVR011 via intravenous (IV) infusion</description>
    <arm_group_label>XVR011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Single dose of normal saline via IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is ≥ 18 years of age.&#xD;
&#xD;
          -  Tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by&#xD;
             RT-PCR and/or antigen test.&#xD;
&#xD;
          -  Had an onset of COVID-19 symptom(s) within 8 days prior to screening; except for&#xD;
             dyspnoea and/or tachypnoea for which an onset within 2 days prior to screening is&#xD;
             applicable.&#xD;
&#xD;
          -  Requires hospitalisation for medical care.&#xD;
&#xD;
          -  Has oxygen saturation &gt;= 91%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requires non-invasive or invasive mechanical ventilation and/or intensive care.&#xD;
&#xD;
          -  Symptoms consistent with severe COVID-19.&#xD;
&#xD;
          -  Has received a monoclonal antibody, plasma from a person who recovered from COVID-19&#xD;
             or any investigational treatment for COVID-19 within 30 days prior to study treatment.&#xD;
&#xD;
          -  Has received an investigational or approved vaccination against SARS-CoV-2 within 14&#xD;
             days prior to study treatment.&#xD;
&#xD;
        NOTE: Other protocol defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Inquiry</last_name>
    <phone>+32 2 899 87 37</phone>
    <email>exevir0101@exevir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

